Using N-acetylcysteine to reduce repetitive behaviors in children with autism
Official title: Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: A Randomized, Controlled Trial
Run by Stanford University · NCT05664789 · Data updated 2026-11-12
This study is testing if a nutritional supplement called N-acetylcysteine can help reduce repetitive behaviors in children with autism aged 3 to 12.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 3 Years to 12 Years |
| Sex | All |
| Enrollment | 144 (estimated) |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Status | Recruiting |
| Started | April 26, 2023 |
| Main results expected | January 31, 2028 |
| Study ends | July 31, 2028 |
| Registry record updated | May 15, 2026 |
| Trial ID | NCT05664789 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 3 to 12 years with a confirmed diagnosis of autism spectrum disorder and moderate severity of restricted and repetitive behaviors.
✕Probably not a fit
Patients with severe symptoms or those who do not meet the eligibility criteria, such as those with significant comorbid conditions, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to investigate the effects of N-acetylcysteine (NAC), a nutritional supplement, on reducing restricted and repetitive behaviors in children diagnosed with autism spectrum disorder. The study will be a 12-week double-blind, randomized, placebo-controlled trial, assessing the neurobiological mechanisms of NAC through neuroimaging techniques such as MRI and EEG. Participants will include children aged 3 to 12 years with confirmed autism diagnoses and moderate severity of symptoms. The trial seeks to provide insights into the clinical benefits of NAC and its potential role in managing autism-related behaviors.
Why it matters
Potential benefit: If successful, this study could provide a new, well-tolerated treatment option for reducing repetitive behaviors in children with autism.
How similar studies have gone: Previous small-scale trials have shown promise for NAC in reducing symptoms of autism, indicating potential for success in this larger trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * children between 3 years and 12 years 11 months * diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview- Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of Symptoms of Autism, or Childhood Autism Rating Scale * at least moderate severity of restricted and repetitive behaviors defined by a Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥ 11 * physical development indicative of prepubescence as defined by criteria for Tanner Stage 1 * if home address is within 300 miles of the primary study site, participants must pass MR safety screening (e.g., no metal in the body) and attempt baseline neuroimaging (MRI or EEG), otherwise baseline neuroimaging is not required for participation * have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days) prior to randomization with no anticipated changes during the trial Exclusion Criteria: * presence of known genetic abnormalities associated with ASD (e.g. Fragile X) * current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia) * presence of significant medical problems * the inability of at least one caregiver to speak and read English to a sufficient level * participants taking glutathione agents/prodrugs * history of any adverse effects to glutathione agents/prodrugs * the inability to drink a sample study compound dissolved in liquid
Where it's running
-
Department of Psychiatry and Behavioral Sciences
Palo Alto, California, United States Recruiting
Study contacts
- Principal investigator: John Hegarty, PhD — Stanford University
- Study coordinator: Ramy Chebbo
- Email: autismresearch@stanford.edu
- Phone: (650)723-7845
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sensory Integration and Deep Pressure Therapy for Motor Coordination in Children with ASD
This study tests whether combining Sensory Integration Therapy with Deep Pressure Therapy can improve motor coordination and reduce repetitive behaviors in children aged 4–10 with autism.
-
Pupillometer screen to help identify autism in kids aged 2–4 during routine visits
A handheld pupillometer test is being tried to see if it can help identify autism in young children during regular pediatric visits.
-
Leopard: using multi-omics to boost genetic diagnosis for neurodevelopmental disorders
This study tests a multi-omics approach to find genetic explanations for neurodevelopmental disorders in people with moderate-to-severe intellectual disability.
-
Heart Rate Variability Biofeedback for Anxiety in Autistic Youth
This study tests a wearable heart rate variability biofeedback tool to see if it helps reduce anxiety in autistic teens.
-
Structured Sensory-Based Occupational Therapy for Children with Autism
This study tests a 12-week, 40-minute sensory-based occupational therapy program twice a week to see if it improves daily skills, sensory processing, movement, and eating in children aged 3-9 with autism.
-
Exergaming and Aerobic Exercise for Kids with Autism
This study tests whether adding exergames or aerobic exercise to a standard program helps improve sleep, movement skills, thinking skills, and brain activity in children with autism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.